Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials

被引：116

作者：

Vetvicka, Vaclav ^{[1
]}

Vannucci, Luca ^{[2
]}

Sima, Petr ^{[2
]}

Richter, Josef ^{[3
]}

机构：

[1] Univ Louisville, Dept Pathol & Lab Med, Louisville, KY 40292 USA

[2] Inst Microbiol, Dept Immunol, Prague 14220, Czech Republic

[3] Zdravotni Ustav Sidlem Usti Nad Labem, Usti Nad Labem 40001, Czech Republic

来源：

MOLECULES | 2019年 / 24卷 / 07期

关键词：

glucan; drug; immunity; food; supplement; infection; mushrooms; PLEUROTUS-OSTREATUS; INNATE IMMUNITY; RESPIRATORY-INFECTIONS; OAT-BRAN; RESISTANCE; RESPONSES; MICE; NUTRITION; CYTOKINES; ANTITUMOR;

D O I：

10.3390/molecules24071251

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Glucans are part of a group of biologically active natural molecules and are steadily gaining strong attention not only as an important food supplement, but also as an immunostimulant and potential drug. This paper represents an up-to-date review of glucans (beta-1,3-glucans) and their role in various immune reactions and the treatment of cancer. With more than 80 clinical trials evaluating their biological effects, the question is not if glucans will move from food supplement to widely accepted drug, but how soon.

引用

页数：17

共 50 条

[41] Publication of clinical drug trials
Nahata, MC
ANNALS OF PHARMACOTHERAPY, 2001, 35 (06) : 780 - 781
[42] Cancer epigenetics: from laboratory studies and clinical trials to precision medicine
Yu, Xinyang
Zhao, Hao
Wang, Ruiqi
Chen, Yingyin
Ouyang, Xumei
Li, Wenting
Sun, Yihao
Peng, Anghui
CELL DEATH DISCOVERY, 2024, 10 (01)
[43] Cancer epigenetics: from laboratory studies and clinical trials to precision medicine
Xinyang Yu
Hao Zhao
Ruiqi Wang
Yingyin Chen
Xumei Ouyang
Wenting Li
Yihao Sun
Anghui Peng
Cell Death Discovery, 10
[44] Review of remote ischemic preconditioning: from laboratory studies to clinical trials
Anttila, Vesa
Haapanen, Henri
Yannopoulos, Fredrik
Herajarvi, Johanna
Anttila, Tuomas
Juvonen, Tatu
SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2016, 50 (5-6) : 355 - 361
[45] From the laboratory concept to clinical trials: the journey of Otoimplant so far
Ziabka, Magdalena
EXPERT REVIEW OF MEDICAL DEVICES, 2019, 16 (02) : 89 - 94
[46] Toxicogenomics in drug discovery: from preclinical studies to clinical trials
Yang, Y
Blomme, EAG
Waring, JF
CHEMICO-BIOLOGICAL INTERACTIONS, 2004, 150 (01) : 71 - 85
[47] Update laboratory testing for clinical trials - Good Clinical Laboratory Practice (GCLP)
Wieland, Eberhard
Kluehe, Cornelia
Shipkova, Maria
LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2013, 37 (06): : 351 - 362
[48] MEANINGFUL INTERPRETATION OF RISK REDUCTION FROM CLINICAL DRUG TRIALS
MCCORMACK, JP
LEVINE, M
ANNALS OF PHARMACOTHERAPY, 1993, 27 (10) : 1272 - 1277
[49] Drug cost avoidance resulting from cancer clinical trials
Bredin, Correne
Eliasziw, Misha
Syme, Rachel
CONTEMPORARY CLINICAL TRIALS, 2010, 31 (06) : 524 - 529
[50] DRUG ANALYSIS IN CLINICAL LABORATORY
SERFONTEIN, WJ
DEVILLIERS, LS
SOUTH AFRICAN MEDICAL JOURNAL, 1977, 51 (25): : 943 - 943

← 1 2 3 4 5 →